Results of a phase II trial of docetaxel (DOC), bevacizumab (BEV), and androgen deprivation therapy (ADT) for biochemical relapse (BCR) after definitive local therapy for prostate cancer (PC).
Rana R. McKay
No relevant relationships to disclose
Kathryn P. Gray
No relevant relationships to disclose
Julia H. Hayes
No relevant relationships to disclose
Glenn J. Bubley
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Philip W. Kantoff
No relevant relationships to disclose
Mary-Ellen Taplin
No relevant relationships to disclose